Practice
Autosomal dominant polycystic kidney disease
Matthew B. Lanktree and Arlene B. Chapman
CMAJ November 13, 2017 189 (45) E1396; DOI: https://doi.org/10.1503/cmaj.170443
Matthew B. Lanktree
Nephrology Division, Department of Medicine (Lanktree), McMaster University, Hamilton, Ont.; Department of Medicine, Section of Nephrology (Chapman), University of Chicago, Chicago, Ill.
MD PhDArlene B. Chapman
Nephrology Division, Department of Medicine (Lanktree), McMaster University, Hamilton, Ont.; Department of Medicine, Section of Nephrology (Chapman), University of Chicago, Chicago, Ill.
MD![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Autosomal dominant polycystic kidney disease
Matthew B. Lanktree, Arlene B. Chapman
CMAJ Nov 2017, 189 (45) E1396; DOI: 10.1503/cmaj.170443
Jump to section
- Article
- Autosomal dominant polycystic kidney disease affects about 1 in 1000 people
- Autosomal dominant polycystic kidney disease is diagnosed by ultrasound
- Supportive care includes management of hypertension, infection and pain
- About 5% of patients will have asymptomatic intracranial aneurysms
- Patients with autosomal dominant polycystic kidney disease should have early referral to a nephrologist
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics